Pharmaceuticals
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
SHANGHAI, Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected infant patients, including the ones in pediat...
2026-08-14 18:18
2967
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the2026 Prix Galien USA Best Startup Award. Innorna was shortlisted in the Best Startup c...
2026-08-13 22:00
3050
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been app...
2026-08-13 09:00
4135
Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026
Following REJURAN®'s TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. GANGNEUNG, South Korea, Aug. 13, 2026 /PRNewswire/ -- PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesth...
2026-08-13 08:00
4518
Osara Health Marks 10 Years with Global Call to Make Cancer Support Beyond Treatment Standard
Launched to mark the company's 10th anniversary, Osara Health's Global Cancer Support Declaration has already secured signatures from healthcare professionals worldwide. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on the human experience of cance...
2026-08-12 23:17
3184
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....
2026-08-12 17:38
3165
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....
2026-08-12 17:10
3197
Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging
VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging MILAN, Aug. 11, 2026 /PRNewswire/ -- Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to ...
2026-08-11 20:00
2361
Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond
* PDRN Derma cream, serum, and mask lineup positions premium K-dermocosmetics based on patented ingredients for Southeast Asian market expansion CHUNCHEON, South Korea, Aug. 11, 2026 /PRNewswire/ -- K-Medichem Co., Ltd. (K-Medichem), a Korean biotech company built on university research, is acc...
2026-08-11 19:17
3175
Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add adva...
2026-08-11 18:00
2455
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...
2026-08-10 19:00
4642
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...
2026-08-10 17:36
3209
Alebund's AP301 NDA Accepted for Review by China's NMPA
SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...
2026-08-07 18:40
3346
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...
2026-08-06 18:46
4052
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Expanded capabilities across Cortellis portfolio help life sciences
organizations turn trusted intelligence into action and accelerate decision
making across the research and development lifecycle
LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc
2026-08-06 16:00
1511
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable de...
2026-08-06 13:17
5910
Telix to Host R&D Day in New York City on September 22, 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional...
2026-08-06 05:00
2810
Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea
Advanced Capsule Technology for Improved Digestive Enzyme Delivery SEOUL, South Korea, Aug. 5, 2026 /PRNewswire/ -- Lonza Capsugel has released new peer-reviewed research showing that its Licaps® DUOCAP® capsule-in-capsule technology can significantly improve the protection and targeted deliv...
2026-08-05 18:39
3314
Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...
2026-08-05 17:37
2417
Sisram Medical Launches Titanium Prime Treatment Concept in Hong Kong SAR
Harnessing dual-device synergies, multi-energy technologies, and pioneering layered protocols, Sisram cements its strategic leadership across APAC HONG KONG, Aug. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices...
2026-08-05 12:11
2471
Week's Top Stories
Most Reposted
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 293 media titles]
2026-09-22 18:37
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 281 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 277 media titles]
2026-09-21 08:00Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 275 media titles]
2026-09-25 14:45
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
12295
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
11010
Dreame Technology Opens New Flagship Store at Suntec City, Expanding Smart Living Experience in Singapore
2026-09-25 18:33
9945
